Bone Turnover Markers and Probable Advanced Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Men and Postmenopausal Women With Type 2 Diabetes

Ningjian Wang, Yuying Wang, Xiaoman Chen, Wen Zhang, Yi Chen, Fangzhen Xia, Heng Wan, Li Q, Boren Jiang, Bin Hu, Yingli LuFrontiers in Endocrinology 2020 · DOI

TL;DR

This study investigates the link between bone turnover markers and non-alcoholic fatty liver disease (NAFLD) progression in individuals with Type 2 diabetes. Researchers found that specific bone markers (N-MID osteocalcin, β-CTX, and P1NP) are associated with the presence of probable non-alcoholic steatohepatitis (NASH) and advanced fibrosis, with notable gender differences in these associations. This highlights a potential "liver-bone axis" in diabetes that could inform future treatment strategies.

What Problem Does This Paper Address?

Type 2 diabetes is strongly linked to a higher incidence of non-alcoholic fatty liver disease (NAFLD), including its more severe forms like non-alcoholic steatohepatitis (NASH) and advanced fibrosis. Simultaneously, NAFLD is known to be associated with impaired bone health, including a history of osteoporotic fractures. However, the specific relationship between bone turnover markers and the progression of NAFLD (from simple fatty liver to NASH and fibrosis) in diabetic patients, particularly considering gender differences, has not been well-established. This paper aims to fill this knowledge gap by exploring how bone turnover markers correlate with the probable presence of NASH and significant fibrosis in a large cohort of Chinese individuals with Type 2 diabetes.

Methods

The researchers conducted a cross-sectional study involving 4,937 diabetic participants from Shanghai, China. To assess NAFLD progression without invasive liver biopsies, they used established non-invasive methods:

  • Probable NASH: Defined by the presence of metabolic syndrome (MetS) in individuals with NAFLD.
  • Probable Advanced Fibrosis: Assessed using the NAFLD Fibrosis Score (NFS), a validated scoring system that estimates the likelihood of bridging fibrosis (stage 3) or cirrhosis (stage 4).

Bone turnover was measured using three key markers:

  • N-MID osteocalcin: A marker of bone formation.
  • β-C-terminal telopeptides of type I collagen (β-CTX): A marker of bone resorption.
  • Procollagen type I N-terminal propeptide (P1NP): Another marker of bone formation.

Statistical analyses, including multinomial logistic regression, were employed to determine the associations between these bone turnover markers and the different stages of NAFLD progression (inflammatory and fibrotic), adjusting for various demographic, metabolic, and clinical factors.

Datasets

The study utilized data from 4,937 diabetic participants enrolled in the METAL study (Environmental Pollutant Exposure and Metabolic Diseases in Shanghai) in 2018. This dataset included sociodemographic information, medical history, lifestyle factors, laboratory results (including HbA1c, liver enzymes, lipid profiles, and bone turnover markers), and anthropometric measurements. No new datasets were introduced, and the study relied on existing clinical data.

Key Insights and Ideas

  • Gender-Specific Associations: The most striking insight is the significant difference in how bone turnover markers relate to NAFLD progression between men and postmenopausal women. This suggests that the interplay between bone and liver health in diabetes is not uniform across genders.
  • Osteocalcin as a Potential NASH Indicator (Women): In postmenopausal women, lower levels of N-MID osteocalcin were associated with a higher probability of NASH. This hints that bone formation markers might be suppressed in women with more severe inflammatory liver disease.
  • Fibrosis Markers Differ by Gender: For fibrosis, P1NP and β-CTX showed positive associations with probable significant fibrosis in postmenopausal women, suggesting increased bone turnover/resorption in this context. Conversely, in men, N-MID osteocalcin and β-CTX were negatively associated with probable fibrosis, indicating a potentially protective or different underlying mechanism.
  • The "Liver-Bone Axis" in Diabetes: The findings strongly support the existence of a "liver-bone axis" in individuals with Type 2 diabetes, where liver health (specifically NAFLD progression) influences bone metabolism, and vice versa. This axis appears to be modulated by gender.

Key Results

  • Postmenopausal Women:
    • Higher quartiles of P1NP and β-CTX were positively associated with the probable presence of significant fibrosis (P for trend <0.001 for P1NP, P for trend 0.025 for β-CTX).
  • Higher quartiles of N-MID osteocalcin were negatively associated with probable NASH (P for trend <0.001).
  • Men:
    • N-MID osteocalcin and β-CTX were negatively associated with the probable presence of significant fibrosis (P for trend 0.029 for N-MID osteocalcin, P for trend 0.027 for β-CTX).
  • Associations between bone turnover markers and probable NASH were less consistent in men compared to women.

Limitations and Future Work

The authors acknowledge several limitations:

  • Cross-Sectional Design: The study cannot establish causality; it only shows associations. Longitudinal studies are needed to confirm these relationships.
  • Single Center Study: The findings might be specific to the population studied and may not be generalizable to other ethnicities or geographic locations.
  • Non-Invasive Assessment: While practical for a large cohort, using ultrasound for steatosis and NFS for fibrosis is less precise than liver biopsy.
  • Distinguishing Bone vs. Liver Sources: The study could not definitively determine whether the measured bone turnover markers originated from bone or the liver, especially for P1NP and β-CTX, which can be influenced by both.
  • BMD Not Measured: Bone mineral density (BMD) was not collected, which would have provided a more comprehensive picture of bone health.

Future work suggested includes:

  • Prospective Studies: To establish causal relationships and understand the temporal sequence of events.
  • Animal Studies: To elucidate the underlying biological mechanisms driving these associations.
  • BMD Measurement: Incorporating BMD assessments in future studies to better understand the link between bone turnover, liver disease, and bone health.
  • Distinguishing Marker Sources: Developing methods to differentiate the hepatic and skeletal origins of bone turnover markers.

Summary updated

Abstract

<b>Objective:</b> Type 2 diabetic patients have a higher incidence of nonalcoholic steatohepatitis (NASH) and advanced stages of fibrosis, and nonalcoholic fatty liver disease (NAFLD) is associated with impaired bone health. We aimed to investigate whether bone turnover is associated with the probable presence of NASH and fibrosis. <b>Methods:</b> In total, 4,937 diabetic participants from Shanghai, China were enrolled in 2018. Subjects with NAFLD were categorized into simple NAFLD and probable NASH groups based on the presence of a metabolic syndrome. The NAFLD fibrosis score was used to identify patients with a higher likelihood of advanced fibrosis. <b>Results:</b> In postmenopausal women, large N-mid fragment of osteocalcin (N-MID osteocalcin) was negatively associated with probable NASH (<i>P for trend</i> < 0.001). β<i>-</i>C-terminal cross-linked telopeptides of type I collagen (β-CTX) and procollagen type I N-terminal propeptide (P1NP) were positively associated with the probable presence of significant fibrosis in postmenopausal women (<i>P for trend</i> 0.015 and <0.001). However, in men, N-MID osteocalcin and β-CTX were negatively associated with the probable presence of significant fibrosis (<i>P for trend</i> 0.029 and 0.027). <b>Conclusions:</b> Significant associations among N-MID osteocalcin, β-CTX and P1NP, and probable advanced NAFLD were observed. Further prospective and animal studies are warranted to understand the causal relationship and underlying mechanism.
BibTeX
@inproceedings{wang2020bone,
  author = {Ningjian Wang and Yuying Wang and Xiaoman Chen and Wen Zhang and Yi Chen and Fangzhen Xia and Heng Wan and Li Q and Boren Jiang and Bin Hu and Yingli Lu},
  title = {{Bone Turnover Markers and Probable Advanced Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Men and Postmenopausal Women With Type 2 Diabetes}},
  booktitle = {Frontiers in Endocrinology},
  year = {2020},
  doi = {10.3389/fendo.2019.00926},
}
Figure